Used in targeted cancer therapies, particularly for B-cell malignancies such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Binds specifically to CD22, a receptor found on the surface of B-cells, enabling selective delivery of cytotoxic agents or immune-mediated destruction of malignant cells. Investigated in antibody-drug conjugates (ADCs) to enhance tumor-specific drug delivery while minimizing damage to healthy tissues. Also utilized in research settings to study B-cell signaling, apoptosis, and immune regulation. Shows potential in overcoming resistance to conventional chemotherapy by modulating B-cell survival pathways.